Evidence map›Paper›PMID 38238771›Full record

ArticleBreast cancer research : BCR2024

Digital image analysis and machine learning-assisted prediction of neoadjuvant chemotherapy response in triple-negative breast cancer.

Timothy B Fisher, Geetanjali Saini, T S Rekha, Jayashree Krishnamurthy, Shristi Bhattarai, Grace Callagy, Mark Webber, Emiel A M Janssen, Jun Kong, Ritu Aneja

Open access · goldAbstract read
In one paragraph

Article in Breast cancer research : BCR, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
25citing papers in PubMed, 1 pooled it
10.4field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

25 citing papers in PubMed, 1 synthesis or guideline pooled it, 30 citations in OpenAlex.

  1. Pooled it
  2. Review
  3. Review
  4. Article
  5. Review
  6. Review
  7. Review
  8. Review
  9. Article
  10. Review
  11. Article
  12. Article
  13. Review
  14. Article
  15. Article
  16. Review
  17. Article
  18. Review
  19. Article
  20. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

10 authors at 5 institutions in 4 countries.

Timothy B FisherDepartment of Biology, Georgia State University, Atlanta, GA, 30302, USA.
Geetanjali SainiSchool of Health Professions, University of Alabama at Birmingham, Birmingham, AL, 35294, USA.
T S RekhaJSSAHER (JSS Academy of Higher Education and Research) Medical College, Mysuru, Karnataka, India.
Jayashree KrishnamurthyJSSAHER (JSS Academy of Higher Education and Research) Medical College, Mysuru, Karnataka, India.
Shristi BhattaraiSchool of Health Professions, University of Alabama at Birmingham, Birmingham, AL, 35294, USA.
Grace CallagyDiscipline of Pathology, University of Galway, Galway, Ireland.
Mark WebberDiscipline of Pathology, University of Galway, Galway, Ireland.
Emiel A M JanssenDepartment of Pathology, Stavanger University Hospital, Stavanger, Norway.
Jun KongDepartment of Mathematics and Statistics, Georgia State University, Atlanta, GA, 30303, USA. jkong@gsu.edu.
Ritu AnejaDepartment of Biology, Georgia State University, Atlanta, GA, 30302, USA. raneja@uab.edu.
Georgia State University · USJSS Academy of Higher Education and Research · INOllscoil na Gaillimhe – University of Galway · IEUniversity of Alabama at Birmingham · USUniversity of Stavanger · NO

Funding

HSET as a racial disparity biomarker for TNBC patientsR01CA239120 · NCI · UNIVERSITY OF ALABAMA AT BIRMINGHAM · PI ANEJA, RITU · 2019 to 2024
$3.0M
Computational pathology software for integrative cancer research with three-dimensional digital slidesU01CA242936 · NCI · GEORGIA STATE UNIVERSITY · PI KONG, JUN, WANG, FUSHENG · 2019 to 2021
$1.1M
NCI NIH HHS R01 CA239120NCI NIH HHS U01 CA242936NIH HHS 1U01CA242936
6 · The paper itself

Abstract

backgroundPathological complete response (pCR) is associated with favorable prognosis in patients with triple-negative breast cancer (TNBC). However, only 30-40% of TNBC patients treated with neoadjuvant chemotherapy (NAC) show pCR, while the remaining 60-70% show residual disease (RD). The role of the tumor microenvironment in NAC response in patients with TNBC remains unclear. In this study, we developed a machine learning-based two-step pipeline to distinguish between various histological components in hematoxylin and eosin (H&E)-stained whole slide images (WSIs) of TNBC tissue biopsies and to identify histological features that can predict NAC response.

methodsH&E-stained WSIs of treatment-naïve biopsies from 85 patients (51 with pCR and 34 with RD) of the model development cohort and 79 patients (41 with pCR and 38 with RD) of the validation cohort were separated through a stratified eightfold cross-validation strategy for the first step and leave-one-out cross-validation strategy for the second step. A tile-level histology label prediction pipeline and four machine-learning classifiers were used to analyze 468,043 tiles of WSIs. The best-trained classifier used 55 texture features from each tile to produce a probability profile during testing. The predicted histology classes were used to generate a histology classification map of the spatial distributions of different tissue regions. A patient-level NAC response prediction pipeline was trained with features derived from paired histology classification maps. The top graph-based features capturing the relevant spatial information across the different histological classes were provided to the radial basis function kernel support vector machine (rbfSVM) classifier for NAC treatment response prediction.

resultsThe tile-level prediction pipeline achieved 86.72% accuracy for histology class classification, while the patient-level pipeline achieved 83.53% NAC response (pCR vs. RD) prediction accuracy of the model development cohort. The model was validated with an independent cohort with tile histology validation accuracy of 83.59% and NAC prediction accuracy of 81.01%. The histological class pairs with the strongest NAC response predictive ability were tumor and tumor tumor-infiltrating lymphocytes for pCR and microvessel density and polyploid giant cancer cells for RD.

conclusionOur machine learning pipeline can robustly identify clinically relevant histological classes that predict NAC response in TNBC patients and may help guide patient selection for NAC treatment.

Indexed as

Breast NeoplasmsTriple Negative Breast NeoplasmsFemaleHumansMachine LearningNeoadjuvant TherapyPrognosisTumor MicroenvironmentDigital image analysisFeature engineeringMachine learningNeoadjuvant chemotherapyTriple-negative breast cancer

Identifiers

PMID38238771
PMCPMC10797728
OpenAlexW4390971849

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.